The purpose of the present study is to formulate Glycyrrhiza glabra root and rhizome aqueous ethanolic extract in microemulsion carrier systems intended for transdermal delivery of incorporated antioxidant actives, flavonoids and polyphenols. The results obtained reveal that the microemulsion system ME3 possesses optimum properties regarding drug content (flavonoids and polyphenols), viscosity, pH, particle size and polydispersity index, zeta potential, stability, permeation of actives and hence possesses high in vitro and ex vivo antioxidant efficacy. These results indicate also that this microemulsion shows approximately 13-fold higher ex vivo antioxidant capacity compared with the liquorice extract solution. In addition, the proposed microemulsion is simple to dispense, cost effective and provides high patient compliance and convenience because of simple topical application and avoidance of non-comfortable oral or parenteral administration.
Two new flavonoids, 8-hydroxyisoscoparin (1) and luteolin 7-O-glucoside 4″-sulfate (2), along with eight known flavonoids, including luteolin 7-O-glucoside 2″-sulfate, were isolated and identified from Washingtonia filifera. All compounds were characterized by 1H-NMR, 13C-NMR, CI-MS, FABMS and UV. The antioxidant activities of various W. filifera extracts were determined.
Boswellia species are trees (family: Bruseraceae) found in India, Northern Africa and the Middle East. This study aims at formulating low dose biologically active fraction from the oleogum resin of Boswellia carterii (BC) in transdermal (TD) microemulsions (MEs) to acquire promoted anti-inflammatory efficacy. The bioactive fraction of the oleogum resin of BC was tested for solubility in different components. The most efficient were selected for constructing phase diagrams for ME preparation. The bioactive fraction was assayed by high performance liquid chromatography for 3-acetyl-11-keto-β-boswellic acid (AKBA), at 210 nm. The bioactive fraction was incorporated in 6 MEs. ME systems were evaluated for drug content and optimized systems were tested for characterization, permeation, skin irritancy and in vivo evaluation of anti-inflammatory activity. Two systems were selected; ME1 and ME4 composed of Tween 80: PEG 400 at 1:1 and 2:1 ratio, with oil content 7.78 and 17.5%, respectively. The systems showed high encapsulation efficiency >83%, small droplet size <100 nm, and suitable pH for topical application. Permeation parameters for ME1 were higher compared to ME4. Both MEs were non irritant. ME1 showed significantly higher anti-inflammatory activity versus the standard TD anti-inflammatory piroxicam. Optimized TD BC MEs could be used as a safe, effective and long acting alternative to oral anti-inflammatories, providing higher and prolonged efficacy and better patient compliance.